LuCED® Lung Test
Early Detection of Lung Cancer
UnknownActive
Key Facts
About VisionGate
VisionGate is a private, pre-revenue diagnostics company developing the LuCED® Lung Test, a non-invasive, AI-powered screening tool for early-stage lung cancer. Its patented Cell-CT™ platform creates high-resolution 3D images of cells from sputum samples, enabling highly accurate detection. Founded in 2007 and based in Phoenix, Arizona, the company is led by a seasoned team with deep experience in medical imaging and diagnostics, and it holds a significant intellectual property portfolio with 35 patents. VisionGate aims to address a critical unmet need in lung cancer screening, particularly for high-risk populations.
View full company profileTherapeutic Areas
Other Early Detection of Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CIZ1B Biomarker Blood Test | Cizzle Biotechnology | Clinical Validation |
| ProLung | Hawkeye Bio | Pre-clinical/Clinical Validation |
| Lung Cancer Detection Program | PrognomiQ | Phase 1 |
| FirstLook Lung | DELFI Diagnostics | Unknown |